Saturn V Capital Management LP
AUSTIN, TX
$697m in 23 US stocks at the end of 30 June 2026. The top 10 are 75.6% of the money. It changed about 12.5% of the portfolio this quarter.
Value
$697m
Stocks
23
Top 10 share
75.6%
Turnover
12.5%
What changed this quarter
New
Bought for the first time this quarter.
- Trevi TherapeuticsTRVI2.8% of the fund
- Sagimet BiosciencesSGMT1.6% of the fund
- Vir BiotechnologyVIR1.1% of the fund
Added
Bought more of a stock they already held.
- Amylyx PharmaceuticalsAMLX11.9% of the fund+6%
- VaxcytePCVX7.1% of the fund+3%
- Immix BiopharmaIMMX6.9% of the fund+26%
- PharvarisPHVS6.5% of the fund+9%
- CelcuityCELC5.6% of the fund+31%
- Disc MedicineIRON5.5% of the fund+17%
- Candel TherapeuticsCADL4.9% of the fund+14%
- X4 PharmaceuticalsXFOR4.7% of the fund+8%
- Dyne TherapeuticsDYN3.4% of the fund+9%
- Zura BioZURA1.8% of the fund+184%
- Oculis Holding AGOCS1.4% of the fund+33%
- Alto NeuroscienceANRO0.7% of the fund+105%
Cut
Sold some of their stake.
- AlumisALMS11.8% of the fund-9%
- Abivax SAABVX9.9% of the fund-4%
- Monopar TherapeuticsMNPR4.1% of the fund-10%
- InvivydIVVD1.0% of the fund-23%
- Ovid TherapeuticsOVID0.3% of the fund-84%
Sold out
Sold their entire stake.
Holdings
- Abivax SAABVX
- Share
- 9.9%
- Value
- $69m
- Shares
- 518,865
-4%
- Satellos BioscienceMSLE
- Share
- 0.4%
- Value
- $3m
- Shares
- 350,000
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Amylyx PharmaceuticalsAMLX | 11.9% | $83m | 4,624,101 | +6% |
| AlumisALMS | 11.8% | $82m | 2,915,443 | -9% |
| Abivax SAABVX | 9.9% | $69m | 518,865 | -4% |
| VaxcytePCVX | 7.1% | $50m | 852,914 | +3% |
| Immix BiopharmaIMMX | 6.9% | $48m | 4,658,429 | +26% |
| PharvarisPHVS | 6.5% | $45m | 1,314,122 | +9% |
| Jazz PharmaceuticalsJAZZ | 5.6% | $39m | 160,938 | Held |
| CelcuityCELC | 5.6% | $39m | 370,318 | +31% |
| Disc MedicineIRON | 5.5% | $38m | 524,730 | +17% |
| Candel TherapeuticsCADL | 4.9% | $34m | 3,303,686 | +14% |
| X4 PharmaceuticalsXFOR | 4.7% | $33m | 6,973,343 | +8% |
| Monopar TherapeuticsMNPR | 4.1% | $29m | 311,976 | -10% |
| Dyne TherapeuticsDYN | 3.4% | $23m | 1,057,493 | +9% |
| Trevi TherapeuticsTRVI | 2.8% | $20m | 1,052,043 | New |
| Zura BioZURA | 1.8% | $12m | 2,101,119 | +184% |
| Sagimet BiosciencesSGMT | 1.6% | $11m | 1,479,918 | New |
| Oculis Holding AGOCS | 1.4% | $9m | 684,880 | +33% |
| Inhibikase TherapeuticsIKT | 1.1% | $8m | 3,869,056 | Held |
| Vir BiotechnologyVIR | 1.1% | $8m | 770,643 | New |
| InvivydIVVD | 1.0% | $7m | 8,392,288 | -23% |
| Alto NeuroscienceANRO | 0.7% | $5m | 182,829 | +105% |
| Satellos BioscienceMSLE | 0.4% | $3m | 350,000 | Held |
| Ovid TherapeuticsOVID | 0.3% | $2m | 663,060 | -84% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 182.6% since 30 June 2025.
Where the money is
Health care90.1%
Other9.9%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.